ImmunoPET Imaging With 89Zr-MPDL3280A in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Bladder Cancer or Triple-negative Breast Cancer Prior to MPDL3280A Treatment

Trial Profile

ImmunoPET Imaging With 89Zr-MPDL3280A in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Bladder Cancer or Triple-negative Breast Cancer Prior to MPDL3280A Treatment

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Mar 2016 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
    • 01 Oct 2015 Planned initiation date changed from 1 Jul 2015 to 1 Oct 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top